Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women 

Efficacy of targeted therapies has enabled unprecedented survival gains in the last few years, but Prof. Jean-Charles Soria believes overcoming drug resistance is likely to be a local battle fought in the tumour microenvironment 

Despite early promises, advances are needed in targeting tumour-specific epitopes, overcoming the tumour microenvironment, and automating CAR-T production, explains Prof. Ulrike Köhl 

New insights into breast cancer immunology and genomics support further segmentation of patient subgroups and treatment approaches, says Prof. Sherene Loi 

With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments 

Promising results with cancer vaccines based on specific antigen mutations in individual tumours, and typically used in combination with checkpoint inhibitors, are fuelling an upsurge of interest in cancer vaccination for patients with established cancer, explains Prof. Pedro Romero. 

The intriguing possibility that altering the microbiome might offer a way of augmenting response to immunotherapy is one of the pioneering new treatment options being explored in oncology.

TAT 2020 Honorary Award recipient Lillian L. Siu, Professor at the University of Toronto and Medical Oncologist at the Princess Margaret Cancer Centre, Toronto, explains the latest progress being made in using ‘bugs as drugs’.